Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 655 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at... April 27, 2021 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer June 27, 2025 What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 Load more HOT NEWS Fine Needle Aspiration Biopsy: How to Prepare and What to Expect First-of-its-kind app for patients on clinical trials being piloted by Cancer... A Follow-Up Not Inferior to Radioiodine Ablation in Patients with Low-Risk... Having Cancer as a Young Adult Put Me on a Path...
